反应详情

6-(3,5-dimethylbenzyl)-5-ethyluracil (see the above Example 4-A) (516 mg, 2 mmol) and 1-acetoxy-2-acetoxymethoxyethane [A. Rosowski, S. H. Kim. M. Wick, J. Med. Chem. (1981) 24, 1177-81]) (704 mg, 4 mmol) were suspended, under nitrogen atmosphere, in acetonitrile (20 ml). It was added thereto HMDS (hexamethyldisilazane) (646 mg, 4 mmol) and TMSCl (chlorotrimethyl-silane) (435 mg, 4 mmol) and the mixture was then stirred for 10 mn. Then it was added dropwise thereto, over 10 mn, a solution of tinIV chloride (625 mg, 2.4 mmol) in acetonitrile (5 ml). After 14 h under stirring, it was added thereto dichloromethane (50 ml) and an aqueous saturated sodium hydrogenocarbonate solution (50 ml). The mixture was extracted with dichloromethane (3×50 ml). The organic phases, collected, were washed with a aqueous saturated sodium hydrogenocarbonate solution (25 ml), with water (25 ml), and then with an aqueous saturated sodium chloride solution. The organic phase was dried (sodium sulfate), concentrated, and then subjected to a flash column chromatography (petroleum ether/ethyl acetate 3:2) to give 1-(2-acetoxyethoxymethyl-6-(3,5-dimethylbenzyl)-5-ethyluracil (690 mg, 92%) in the form of a white solid.

1. additionIt was added
2. additionThen it was added dropwise
3. additionit was added
4. extractionThe mixture was extracted with dichloromethane (3×50 ml)
5. customThe organic phases, collected
6. washwere washed with a aqueous saturated sodium hydrogenocarbonate solution (25 ml), with water (25 ml)
7. dry with materialThe organic phase was dried (sodium sulfate)
8. concentrationconcentrated